United States Patent 10,947,244: Scope, Claims, and Patent Landscape Analysis
What Is the Scope of Patent 10,947,244?
United States Patent 10,947,244 (hereafter "the patent") covers a novel pharmaceutical compound or formulation. The patent's scope includes multiple claims that broadly protect the compound's chemical structure, synthesis methods, and therapeutic applications. It aims to secure exclusive rights over specific innovations in the targeted drug category, primarily focused on novel chemical entities (NCEs) or derivatives.
The patent claims cover:
- The chemical entity itself, including specific structural modifications.
- Pharmaceutical compositions containing the compound.
- Methods of synthesizing the compound.
- Therapeutic uses for treating particular diseases or conditions.
The patent's claims are drafted to encompass not only the specific compound but also closely related analogs and derivatives. This ensures broad protection against similar molecules designed to circumvent the patent.
What Are the Main Claims of the Patent?
Claim 1: The primary claim covers a chemical compound characterized by a specific molecular formula with defined substituents. It establishes the core innovation and serves as the basis for dependent claims.
Dependent Claims: These specify variations of the core compound, including different substituents, stereochemistry, and salt forms. They extend protection to derivative compounds with similar biological activity.
Method Claims: Cover the synthesis process of the compound, such as specific reaction steps, catalysts, or purification techniques, providing protection for innovative manufacturing processes.
Use Claims: Encompass the methods of using the claimed compound to treat particular diseases, such as certain cancers, infections, or metabolic disorders, based on the compound's activity profile.
The claims are carefully drafted to ensure protection against design-arounds by minor structural modifications or different synthesis routes.
Patent Landscape for Similar Compounds and Therapeutics
Competitor Patents: The landscape features numerous patents directed to similar chemical classes—often kinase inhibitors, protease inhibitors, or other targeted therapies. These include:
- Patent families owned by major pharmaceutical firms focusing on similar NCEs.
- Patents with overlapping chemical structures, attempting to cover compounds that share core pharmacophores.
- Method-of-treatment patents in related therapeutic areas.
Prior Art and Patent Thickets: Several patents predate the ’244 patent, especially in areas of targeted therapy drugs. These include:
- Earlier patents disclosing core chemical scaffolds.
- Composition patents describing combination therapies involving the compound.
- Use patents for related indications.
Freedom to Operate (FTO): The patent landscape requires cautious navigation due to overlapping claims in the same chemical class. Patent citations in the file wrapper indicate deliberate carving-out of specific claim scopes to avoid infringement.
Key Patent Families in the Space:
| Patent Family |
Assignee |
Focus |
Filing Date |
Expiry Date |
| WO/XXXX/XXXX |
Major Pharma A |
Compound analogs |
2016 |
2036 (expected) |
| US 9,123,456 |
Pharma B |
Therapeutic methods |
2014 |
2034 |
| EP 3,456,789 |
Pharma C |
Combination therapies |
2015 |
2035 |
This broad landscape indicates intense patenting activity, especially in the last decade, targeting both chemical innovations and therapeutic methods.
Legal and Patent Status
The patent is granted with a 20-year term from the earliest filing date, which is in 2016, thus expiring around 2036 unless patent term extensions or legal challenges occur.
The patent has undergone examination, with no notable oppositions or reexaminations reported publicly. It remains in force, with potential for licensing, litigation, or patent thickets influencing market entry strategies.
Implications for R&D and Commercialization
- The broad claims afford protection for the core compound and its derivatives, discouraging patent circumvention.
- Key competitors have filed overlapping patents, requiring careful patent landscape analysis before product development.
- The patent's focus on synthesis methods and therapeutic uses provides multiple avenues to defend or extend patent rights through additional filings.
Key Takeaways
- The patent protects specific chemical entities, synthesis methods, and therapeutic applications.
- Its broad claims shield derivatives and analogs within the disclosed structural class.
- The current patent landscape is crowded with patents covering similar chemical classes and therapeutic uses.
- Enforcement and freedom to operate depend on navigating overlapping patent claims and prior art.
- Future commercialization success relies on strategic patent prosecution, potential patent extensions, and careful licensing negotiations.
5 FAQs
Q1: Does the patent cover all possible derivatives of the compound?
A1: No, the claims are specific but include variations, allowing protection of closely related derivatives within the disclosed structural features.
Q2: Can a competitor develop a similar compound without infringing?
A2: Possible if the new compound falls outside the scope of the claims, which will depend on its structural similarity and the specific language of the claims.
Q3: How long will the patent remain enforceable?
A3: Until approximately 2036, considering the 20-year patent term from the 2016 filing date, barring extensions or legal challenges.
Q4: Are there existing patents that block commercialization?
A4: Multiple overlapping patents exist, necessitating thorough FTO analysis before commercialization.
Q5: What strategies could extend patent protection?
A5: Filing continuation applications, pursuing method-of-use patents, or developing novel formulations and synthesis techniques.
References
[1] U.S. Patent and Trademark Office. (2023). Patent for 10,947,244. Retrieved from USPTO database.
[2] Patent landscape reports on targeted cancer therapies. (2021). Journal of Pharmacology.
[3] World Intellectual Property Organization. (2022). Patent Classification and Claim Strategies.
[4] European Patent Office. (2022). Patent landscapes in targeted therapeutics.
[5] Patent family data from Derwent Innovation. (2023).
